Shattuck Labs, Inc.

STTK

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001680367

C

middle fifth of 369 graded peers in healthcare

rank 159 of 369; percentile 42.9; sampling error 2.5 points; lower is stronger

A B C D E

C, the tortoise



Scoreboard	
Profitability	B/C percentile 41.4
Solvency	B percentile 30.0
Growth and financing	D percentile 67.6
Reliability	0.83 AUC filers with $12.5M to $120M assets; 95% interval 0.79 to 0.86; 201 events, 2020 to 2025
Peer failure rate	1.07% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$12.5M to $120M assets total assets $91.0M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Mar 5, 2026 241 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026
Last close	$5.57 2026-10-30; market equity $559.0M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 5, 2026

We are a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific Death Receptor 3 ("DR3") blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Our expertise in protein engineering and the development of novel tumor necrosis factor ("TNF") receptor therapeutics come together in our lead program, SL-325, a potentially first-in-class DR3 blocking antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway than TL1A blocking antibodies. SL-325 is a high-affinity DR3 blocking monoclonal antibody.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 41.4						
Gross profitability	not computable	32.4%				
one or more required annual facts are missing						

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Return on invested capital	not computable	9.3%			
one or more required annual facts are missing					
Accruals ratio	(9.8%)	(6.6%)	41.4	803	2025-12-31
Gross margin stability, five years	not computable	2.8 pts			
five annual gross margins are required; found 0					
Solvency, sleeve percentile 30.0					
Twelve-month failure probability	0.04%	0.08%	26.5	246	2026-06-30
Altman Z double-prime	(3.77)	(0.35)	50.5	748	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
one or more required annual facts are missing					
Current ratio	11.70x	2.92x	12.9	829	2025-12-31
Growth and financing, sleeve percentile 67.6					
Revenue growth, three-year compound	15.3%	10.1%	39.7	412	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
current FCF must be positive and base FCF must exceed $100,000					
Reinvestment rate	not computable	37.1%			
one or more required annual facts are missing					
Asset growth, three years	(23.7%)	2.2%	87.6	696	2025-12-31
Net share issuance, one year	49.4%	2.5%	75.4	631	2026-02-26

Warnings

1 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 49.4%

Among 369 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
154	Medtronic plc (MDT)	41.6	B/C	
155	Xeris Biopharma Holdings, Inc. (XERS)	41.8	B/C	
156	Nephros Inc. (NEPH)	42.1	B/C	fortress balance sheet
157	Sight Sciences, Inc. (SGHT)	42.4	B/C	fortress balance sheet
158	Myomo, Inc. (MYO)	42.7	C	fortress balance sheet
159	Shattuck Labs, Inc. (STTK)	42.9	C	dilution
160	Ligand Pharmaceuticals Inc. (LGND)	43.2	C	
161	Immucell Corp. (ICCC)	43.5	C	
162	NovoCure Ltd. (NVCR)	43.8	C	fortress balance sheet
163	Addus HomeCare Corp. (ADUS)	44.0	C	
164	Avita Medical, Inc. (RCEL)	44.3	C	short runway

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-30 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	255.2%	(2.2%)	98
Distance from 52-week high	(31.0%)	(28.7%)	47
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	(7.2%)	(1.0%)	37
Book value to price	0.38	0.28	60
Sales to price	0.00	0.30	3
Composite equity issuance, five years	87.6%	20.5%	75
Relative strength against the sector, log excess return	1.10	(0.19)	98

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$63.3M
Operating cash flow, four quarters	-$41.0M
Months of runway	18.5
Days since last periodic filing	82 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	$6.2M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-$48.8M	2025-12-31	2026-03-05	10-K	26-014989
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$39.9M	2025-12-31	2026-03-05	10-K	26-014989
3	assets	us-gaap:Assets	$91.0M	2025-12-31	2026-03-05	10-K	26-014989
4	assets	us-gaap:Assets	$91.0M	2024-12-31	2026-03-05	10-K	26-014989
5	current assets	us-gaap:AssetsCurrent	$82.5M	2025-12-31	2026-03-05	10-K	26-014989
6	current liabilities	us-gaap:LiabilitiesCurrent	$7.1M	2025-12-31	2026-03-05	10-K	26-014989
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$430.5M	2025-12-31	2026-03-05	10-K	26-014989
8	operating income	us-gaap:OperatingIncomeLoss	-$51.5M	2025-12-31	2026-03-05	10-K	26-014989
9	book equity	us-gaap:StockholdersEquity	$82.4M	2025-12-31	2026-03-05	10-K	26-014989
10	liabilities	us-gaap:Liabilities	$8.6M	2025-12-31	2026-03-05	10-K	26-014989
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.0M	2025-12-31	2026-03-05	10-K	26-014989
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$5.7M	2024-12-31	2026-03-05	10-K	26-014989
13	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.7M	2023-12-31	2025-03-27	10-K	25-000012
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$652,000	2022-12-31	2024-02-29	10-K	24-000014
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$71,000	2025-12-31	2026-03-05	10-K	26-014989
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$60.5M	2024-12-31	2026-03-05	10-K	26-014989
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$59,000	2024-12-31	2026-03-05	10-K	26-014989
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$81.2M	2023-12-31	2025-03-27	10-K	25-000012

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$407,000	2023-12-31	2025-03-27	10-K	25-000012
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$94.5M	2022-12-31	2024-02-29	10-K	24-000014
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$11.6M	2022-12-31	2024-02-29	10-K	24-000014
22	assets	us-gaap:Assets	$159.6M	2023-12-31	2025-03-27	10-K	25-000012
23	assets	us-gaap:Assets	$205.3M	2022-12-31	2024-02-29	10-K	24-000014
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	71,564,217	2026-02-26	2026-03-05	10-K	26-014989
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	47,899,240	2025-04-01	2025-05-01	10-K/A	25-000028

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.